BioCentury | Oct 13, 2020
Finance

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

...peptides for cancer, autoimmunity, pain and inflammation. TargetsPP2A – Protein phosphatase 2A BC Staff Evotec SE Canaan Cedilla Therapeutics Inc. EdiGene Inc. Rappta Therapeutics LLC chs2020...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cancer

...to MEK inhibitors, the PP2A activator decreased tumor volume compared with vehicle. Next steps by Rappta Therapeutics LLC...
...cancer (CRPC). TARGET/MARKER/PATHWAY: Protein phosphatase 2 (PP2A; PPP2CA), KRAS (K-Ras) LICENSING STATUS: Patented; licensed to Rappta Therapeutics LLC...
...jukwes@utu.fi CONTACT: Goutham Narla, Case Western Reserve University, Cleveland, Ohio email: gnarla@med.umich.edu Sandi Wong Case Western Reserve University Rappta Therapeutics LLC University...
Items per page:
1 - 2 of 2
BioCentury | Oct 13, 2020
Finance

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

...peptides for cancer, autoimmunity, pain and inflammation. TargetsPP2A – Protein phosphatase 2A BC Staff Evotec SE Canaan Cedilla Therapeutics Inc. EdiGene Inc. Rappta Therapeutics LLC chs2020...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cancer

...to MEK inhibitors, the PP2A activator decreased tumor volume compared with vehicle. Next steps by Rappta Therapeutics LLC...
...cancer (CRPC). TARGET/MARKER/PATHWAY: Protein phosphatase 2 (PP2A; PPP2CA), KRAS (K-Ras) LICENSING STATUS: Patented; licensed to Rappta Therapeutics LLC...
...jukwes@utu.fi CONTACT: Goutham Narla, Case Western Reserve University, Cleveland, Ohio email: gnarla@med.umich.edu Sandi Wong Case Western Reserve University Rappta Therapeutics LLC University...
Items per page:
1 - 2 of 2